Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.
Hummel HD, Kufer P, Grüllich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, Goebeler ME, Miller K, de Santis M, Loidl W, Dittrich C, Buck A, Lapa C, Thurner A, Wittemer-Rump S, Koca G, Boix O, Döcke WD, Finnern R, Kusi H, Ajavon-Hartmann A, Stienen S, Sayehli CM, Polat B, Bargou RC. Hummel HD, et al. Among authors: kufer p. Immunotherapy. 2021 Feb;13(2):125-141. doi: 10.2217/imt-2020-0256. Epub 2020 Nov 10. Immunotherapy. 2021. PMID: 33172323 Free article. Clinical Trial.
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N, Brandl C, Lippold S, Cobb K, Brasky K, Leo E, Bargou R, Murthy K, Baeuerle PA. Schlereth B, et al. Among authors: kufer p. Cancer Immunol Immunother. 2006 May;55(5):503-14. doi: 10.1007/s00262-005-0001-1. Epub 2005 Jul 20. Cancer Immunol Immunother. 2006. PMID: 16032400 Free PMC article.
Blinatumomab: a historical perspective.
Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Nagorsen D, et al. Among authors: kufer p. Pharmacol Ther. 2012 Dec;136(3):334-42. doi: 10.1016/j.pharmthera.2012.07.013. Epub 2012 Aug 24. Pharmacol Ther. 2012. PMID: 22940266 Review.
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, Noppeney R, Hess G, Kallert S, Mackensen A, Rupertus K, Kanz L, Libicher M, Nagorsen D, Zugmaier G, Klinger M, Wolf A, Dorsch B, Quednau BD, Schmidt M, Scheele J, Baeuerle PA, Leo E, Bargou RC. Goebeler ME, et al. Among authors: kufer p. J Clin Oncol. 2016 Apr 1;34(10):1104-11. doi: 10.1200/JCO.2014.59.1586. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884582 Clinical Trial.
The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct.
Brandl C, Haas C, d'Argouges S, Fisch T, Kufer P, Brischwein K, Prang N, Bargou R, Suzich J, Baeuerle PA, Hofmeister R. Brandl C, et al. Among authors: kufer p. Cancer Immunol Immunother. 2007 Oct;56(10):1551-63. doi: 10.1007/s00262-007-0298-z. Epub 2007 Feb 20. Cancer Immunol Immunother. 2007. PMID: 17310380 Free PMC article.
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gökbuget N, Neumann S, Goebeler M, Viardot A, Stelljes M, Brüggemann M, Hoelzer D, Degenhard E, Nagorsen D, Baeuerle PA, Wolf A, Kufer P. Klinger M, et al. Among authors: kufer p. Blood. 2012 Jun 28;119(26):6226-33. doi: 10.1182/blood-2012-01-400515. Epub 2012 May 16. Blood. 2012. PMID: 22592608 Free article. Clinical Trial.
79 results